It’s arguably the number one question I get in clinic: 'Wait, isn’t ketamine addictive?' I appreciate the concern—honestly, you should be asking that. The short answer is that while recreational misuse of this drug can absolutely lead to a dependency loop, medically supervised, low-dose ketamine therapy is a completely different animal. Context is everything here. [1]
The mechanics of addiction
When we talk about substance dependence, we’re usually looking for three main ingredients: massive or constantly increasing doses, compulsive daily use, and an unstructured environment that fuels the behavior. Recreational use hits all three—big doses, used often, in social settings. Clinical therapy is built from the ground up to dismantle those risk factors one by one. [2]
Why supervision changes the safety profile
- We use fixed, low doses that are a fraction of what people take recreationally.
- The schedule is rigid—usually two or three times a week—so you aren't reaching for it on-demand.
- Prescriptions are tightly tracked and limited in quantity to prevent any 'extra' dosing.
- We screen every single patient for a history of substance use before we even think about a script.
- Every session is framed around therapy and integration rather than just 'escaping'.
Looking at the actual data
In the published trials covering supervised ketamine—whether that's IV infusions, nasal esketamine, or the oral programs we manage—clinically significant misuse is remarkably rare. Most cases of ketamine use disorder come from the recreational world. These are folks taking huge amounts outside of any medical guardrails, which just doesn't happen in a structured clinical program. [3]
When we say 'no' to ketamine
Ketamine is a powerful tool, but it’s not for everyone. Some patients have medical or psychological histories where the risk-benefit math just doesn't work out. My job is to protect you, which is why we generally rule it out for: [1]
- Anyone with a current or past history of abusing dissociative drugs.
- People dealing with active psychosis or bipolar disorder that isn't stable.
- Folks with uncontrolled high blood pressure or serious heart issues.
- Those who are currently pregnant.
- Patients who can't ensure a sober 'sitter' is there with them during a session.
Let’s talk about other risks
At the doses we use, side effects are usually gone in about an hour or two. You might feel sleepy, a bit nauseous, or have a temporary spike in blood pressure. You’ll see headlines about bladder irritation or cognitive issues, but pay attention to the fine print—those are almost exclusively seen in heavy, high-dose recreational users, not in patients on a controlled therapeutic protocol.
Real talk
Low-dose ketamine therapy has a solid safety record in patients who are properly vetted. Look—no medication is 100% risk-free. However, when a clinician is managing your dose, your schedule, and your supply, the risk of developing an addiction is very low. Just be honest with us about your history during intake. We’ll be straight with you about whether this is the safest path for your brain.
Available across Florida
Reset My Vitality is a Florida-licensed telehealth practice. The treatments covered in this guide are available to patients statewide, with medication shipped directly to your door. Explore the program for your city:
- Mental Health in Miami, FL
- Mental Health in Miami Beach, FL
- Mental Health in Fort Lauderdale, FL
- Mental Health in West Palm Beach, FL
- Mental Health in Boca Raton, FL
- Mental Health in Orlando, FL
- Mental Health in Tampa, FL
- Mental Health in Jacksonville, FL
- Mental Health in Naples, FL
Key Clinical Studies
A short, responsible summary of recent peer-reviewed research relevant to this topic. This is for education only, not medical advice.
Efficacy of ketamine therapy in the treatment of depression
Indian Journal of Psychiatry · 2019
Key finding: Subanesthetic ketamine (0.5 mg/kg IV) produced robust, rapid antidepressant effects that were visible immediately and largely sustained at one month in patients with depression.
Why it matters: Supports the rapid onset and structured dosing protocol used in our at-home low-dose ketamine program.
View studyExtended-release ketamine tablets for treatment-resistant depression
Nature Medicine · 2024
Key finding: 180 mg twice-weekly extended-release ketamine tablets significantly improved MADRS scores vs placebo in treatment-resistant depression, with good tolerability and mostly at-home dosing.
Why it matters: Demonstrates that controlled at-home ketamine delivery can be both safe and effective for difficult-to-treat cases.
View studyKetamine vs ECT for non-psychotic treatment-resistant major depression
New England Journal of Medicine · 2023
Key finding: Intravenous ketamine was non-inferior to electroconvulsive therapy for non-psychotic treatment-resistant depression, with roughly 55% of ketamine patients showing sustained improvement.
Why it matters: Reinforces ketamine as a credible option for patients who have not responded to traditional antidepressants.
View studyScientific References
Peer-reviewed studies and reviews cited in this article.
- [1]Glue P, et al. Extended-release ketamine tablets for treatment-resistant depression. Nat Med. 2024. View study
- [2]Yavi M, et al. Ketamine treatment for depression: a review. 2022. View study
- [3]Tully JL, et al. Ketamine treatment for refractory anxiety: A systematic review. 2022. View study
